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This study evaluates whether the integration of pharmacists into health-care teams through the delivery 
of pharmaceutical care-based medication therapy management (MTM) services can improve the clinical 
outcomes of patients with chronic health conditions in the primary health-care setting. A retrospective 
descriptive study of 92 outpatients assisted by MTM pharmacists in primary health-care units was carried 
out over 28 months (median follow-up: 05 months). Patients were followed up by MTM pharmacists, 
with a total of 359 encounters and a ratio of 3.9 encounters per patient. The prevalence of hypertension, 
diabetes mellitus and dyslipidaemia was 29.5%, 22.0% and 19.4%, respectively. There was a high 
prevalence of drug-related problems with a ratio of 3.4 per patient. Pharmacists performed a total of 307 
interventions to prevent or resolve drug-related problems. With regard to control of the most prevalent 
chronic medical conditions, a high percentage of patients reached their therapy goals by the last encounter 
with the pharmacist: 90.0% for hypertension, 72.3% for diabetes mellitus and 90.3% for dyslipidaemia. 
MTM services provided by pharmacists resolved drug therapy problems and improved patients’ clinical 
outcomes. This study provides evidence for health-care managers of the need to expand the clinical role 
of pharmacists within the Brazilian public health-care system.
Uniterms: Pharmaceutical care/primary care. Medication therapy management. Chronic health/
conditions. Pharmacists/professional practice/Brazil
INTRODUCTION
In pharmaceutical care practice the pharmacist takes 
responsibility for meeting patients’ drug-related needs by 
detecting and resolving drug-related problems (DRPs). In 
this study, this professional practice is materialized into the 
clinical service known as medication therapy management 
(MTM). MTM services follow the philosophy and patient 
care process of pharmaceutical care practice as proposed 
by Cipolle, Strand and Morley (2012) and, for this reason, 
they are called “pharmaceutical care-based MTM” 
(Ramalho de Oliveira, 2009; Obreli Neto et al., 2011; 
de Souza et al., 2007; Lee, Grace, Taylor, 2006; Cipolle, 
Strand, Morley, 2012). 
Various studies have demonstrated the positive 
impact of pharmaceutical care practice on patients’ 
health outcomes. A recently published study showed 
that exposure to face-to-face MTM services resulted 
in improvement of medication adherence measured 
by proportion of days covered across multiple chronic 
disease medication classes (Brummel, Carlson, 2016). 
Fikri-Benbrahim et al. (2013) showed that adherence to 
antihypertensive therapy in a pharmacist intervention 
group was 4.07 times higher than in a control group. Tan et 
al. (2014) demonstrated that the integration of pharmacists 
into primary care clinics had positive effects on primary 
outcomes related to medication use or clinical outcomes. 
Strand et al. (2004) showed that 88.0% of patients’ DRPs 
were resolved by pharmacists, while Borges et al. (2010) 
successfully resolved 62.7% of the identified DRPs. 
 Despite the potential impact of pharmaceutical 
care on medication use, and while professionals and 
researchers in developed countries are involved in 
understanding and improving the sustainability of MTM 
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services (Sorensen et al., 2016), these are still limited 
in developing countries such as Brazil. Pharmacists in 
developing countries work mainly in activities related 
to acquisition and inventory control of drugs, with little 
involvement in direct patient care (Obreli Neto et al., 
2011). There are a few published studies on the clinical 
outcomes of this practice in Brazil, mainly in the primary 
care setting (Mourão et al., 2013; Obreli Neto et al., 2011; 
Obreli Neto, Cuman, 2010; Lyra Júnior, Marcellini, Pelá, 
2008; de Souza et al., 2007; Lyra Júnior et al., 2007). 
Primary care is the main option for access to health 
care for approximately 70% of the Brazilian population 
(Obreli Neto et al., 2011). In primary care, the high 
prevalence of chronic conditions is associated with an 
increase in the use of medications Obreli Neto et al., 
2011; Lee, Grace, Taylor, 2006). Also, the high use of 
medications is associated with the development of DRPs, 
which can negatively impact on patients’ health and 
increase the total health-care costs (Obreli Neto et al., 
2011; Lee, Grace, Taylor, 2006; Cipolle, Strand, Morley, 
2012). 
The aim of this study was to evaluate whether the 
integration of pharmacists into health-care teams through 
the delivery of pharmaceutical care-based medication 
therapy management services can improve the clinical 
outcomes of patients with chronic health conditions in the 
primary care setting. 
PATIENTS AND METHODS
A retrospective descriptive study was conducted 
including all patients (n=92) assisted by MTM pharmacists 
in primary health-care units in Divinópolis (MG, Brazil) 
between October 2010 and February 2013. 
Ethical approval
The study was conducted following the Declaration 
of Helsinki guidelines (WMO, 1996) and the provisions of 
the Brazilian National Health Committee. The Institutional 
Human Experimentation Committee of UFSJ (No. 
007/2011) approved it.
Setting
MTM services were provided in three units of the 
Family Health Strategy (FHS) in the city of Divinópolis, 
Minas Gerais, Brazil. Two clinical faculties, three 
pharmacy students and one pharmacist from the local 
health system composed the team. The criteria for patient 
referral to the MTM service were: multiple medication use 
(two or more medications), old age (≥ 60 years), lack of 
response to treatment, presence of adverse drug reactions 
and non-adherence to the prescribed treatment. Patients 
were eligible if they met at least one criterion. The number 
and frequency of appointments were individualized 
according to the patient’s needs (weekly, fortnightly or 
monthly) and the interventions were implemented either 
directly with the patient or with the physician.
Data collection and analysis
Data were collected from the patient’s medical 
record. The first consultation was called “before initiating 
delivery of MTM services” and “abandonment of service” 
or “final data collection (February of 2013)” was identified 
as “after delivery of MTM services”. A coded structured 
instrument was constructed, which included: clinical 
conditions according to the International Classification 
of Diseases-10 (WHO, 1992), pharmacotherapy utilized 
[according to the Anatomical Therapeutic Chemical 
Code (WHO, 2012), medicine dosage forms and duration 
of treatment], clinical status of the patient according to 
the established goals of therapy, DRPs, interventions 
implemented by the pharmacist and the therapy goals 
achieved. The data were stratified by polypharmacy (use 
of five or more medications) according to Flores and 
Mengue (2005).
To analyze the results, we used the theoretical 
framework proposed by Cipolle, Strand and Morley 
(2012) for the description of the pharmacotherapeutic 
needs, types of DRPs and the categorization of 
pharmacist interventions. The following parameters 
were utilized in assessing whether or not the therapy 
goals were met: hypertension, blood pressure ≤ 139/89 
mmHg (Dipiro et al., 2011); type 2 diabetes mellitus, 
pre- and postprandial glucose levels of < 130 mg/dL 
and <180 mg/dL, respectively (Dipiro et al., 2011); 
hyperlipidaemia, LDL < 130 mg/dL (Semla, Beizer, 
Higbee, 2012); anxiety disorder, absence of insomnia, 
muscle tension, irritability or restlessness (Young et 
al., 2005); major depression, absence of changes in 
sleep, appetite, daily accomplishment of tasks, absence 
of distress and suicide ideation (Young et al., 2005); 
osteoporosis, the absence of fractures, reduction of pain, 
increase in functional capacity and maintenance of bone 
mass (Dipiro et al., 2011); pain, absence of pain (Dipiro 
et al., 2011); hypothyroidism, free T4 in the range of 
5.0–12.0 mcg/dL and TSH in the range of 0.4–4.5 mU/L 
(Young et al., 2005); dyspepsia, lack of heartburn and 
stomach discomfort (Dipiro et al., 2011); and epilepsy 
and absence of seizure (Dipiro et al., 2011).
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As proposed by Cipolle, Strand and Morley (2012), 
in this study the health status was used to measure patients’ 
clinical outcomes. The clinical outcome status of each 
of the patients’ medical conditions was assessed by the 
research team at the last MTM visit and compared with the 
baseline health status using data from the patient’s medical 
record. The baseline health status was classified as positive 
when the health condition was controlled and negative 
when it was not controlled. According to Cipolle, Strand 
and Morley (2012), the clinical outcome status at the last 
MTM visit was considered positive when it was classified 
as “resolved”, “stable”, “improved” or “partially improved”. 
The following categories were used when the clinical status 
was considered negative: “no improvement”, “worsened”, 
“therapeutic failure” and “death”. 
For data analysis, the database was set up using 
the technique of double entry and processed using the 
Statistical Package for the Social Sciences (SPSS – version 
22). Statistics consisted of measures of central tendency, 
variability and proportions. McNemar’s test was used 
to verify the effect of pharmacist intervention. This test 
examines treatment effect and tests the hypothesis that the 
change in proportions between the different time points is 
due to chance. Thus, when we reject this hypothesis, we 
can say that there is evidence of a treatment effect (Pagano, 
Gauvreau, 2004).
RESULTS
The median age of patients was 63.0 years and 
67.4% (n=62) were females. With regard to the follow-up 
of patients, there were 359 consultations with a median of 
3.9 per patient. Three hundred and twenty health problems 
were found, with a median of 3.5 per patient. 
Ten medical conditions represented 83.8% (n=268) 
of the total reported. The most prevalent medical 
conditions were: hypertension (29.5%), type 2 diabetes 
mellitus (22.0%) and dyslipidemia (19.4%). Dyspepsia, 
type 2 diabetes mellitus and dyslipidemia had the greatest 
proportion of patients who had uncontrolled disease: 
80.0%, 66.0% and 54.1%, respectively (Table I).
Most medications were prescribed for the treatment 
and control of non-communicable diseases (NCDs) such 
as hypertension, diabetes and dyslipidemia. The 15 most 
commonly used drugs accounted for 65.3% of the total 
number of drugs (Table II). On average, each patient used 
6.0 different medications.
During MTM visits, 316 DRPs were detected with 
an average of 3.4 DRPs per patient and 88.6% of DRPs 
were related to polypharmacy. The most prevalent DRP 
was adverse reaction (31.0%) (Table III). 
The causes of DRPs were the following: 24.1% 
(n=71) undesirable effect, unsafe medication, presence of 
a contraindication and treatment of preventable adverse 
reactions; 22.4% (n=66) drug interactions; 7.8% (n=23) 
frequency, dosage and/or incorrect administration; 7.5% 
(n=22) lack of clinical indication; 6.1% (n=18) patient 
preference for drug cessation; 5.8% (n=17) patient failure 
to understand instructions; 4.8% (n=14) high dose; 4.4% 
(n=13) duplicate therapy; 4.1% (n=12) ineffective dose 
(low dose); 3.7% (n=11) more effective drug available or 
the drug is not indicated for the condition; and 9.5% (n=28) 
were related to other problems. 
A total of 307 interventions were performed, and 
most of them contributed to the achievement of the 
patient’s therapeutic goal. The most common intervention 
was medication change (Table IV).
At the beginning of the MTM service (at baseline), 
the clinical status of the patients’ medical conditions was 
considered negative in almost half of the times, 47.5%. 
After the service was delivered, the final evaluation 
showed that 83.9% (n=156) of the clinical status was 
positive (Table I). In 21.2% (n=65) of interventions there 
was no record about its impact on the goal of therapy.
DISCUSSION
The high prevalence of polypharmacy in this 
study can be explained by the fact that it was one of 
the criteria for referral to MTM services. However, the 
high prevalence of chronic diseases also contributed to 
polypharmacy (Sousa et al., 2012; Flores, Mengue, 2005). 
The high incidence of DRPs in patients with polypharmacy 
has also been shown in other studies (Correr et al., 2007; 
Koh et al., 2005).
The therapeutic goal at the first MTM visit of most 
of the health conditions associated with polypharmacy, 
especially hypertension, diabetes and dyslipidaemia, was 
not being achieved. As shown in the present study and in 
previously published research, MTM services represent 
an effective strategy for the resolution of DRPs, which 
can significantly improve patients’ clinical outcomes 
(Tan et al., 2014; Fikri-Benbrahim et al., 2013; Zaman 
Huri, Chai Ling, 2013; Mourão et al., 2013; Obreli Neto 
et al., 2011; Alencar et al., 2011; Correr et al., 2011; 
Borges et al., 2010; Obreli Neto, Cuman, 2010). In a study 
examining 10 years of pharmaceutical care services in 
Minnesota, Ramalho de Oliveira et al. (2010) also pointed 
out the importance of pharmacist-delivered medication 
management services for the control of hypertension, 
diabetes and dyslipidemia. 
Interestingly, in the case of psychiatric disorders, 
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there was not much difference in the attainment of 
therapeutic goals before and after service delivery. 
This may reflect the difficulty in objectively measuring 
clinical results or a deficiency in the skills of pharmacists 
in evaluating the subjective parameters utilized in 
mental health. In the case of osteoporosis, all patients 
were taking alendronate sodium and were achieving 
their therapeutic goals at the beginning of the study. The 
TABLE I – Analysis of patients regarding the clinical outcome status of their medical conditions before and after initiating the 
delivery of MTM services, stratified by polypharmacy
Medical 
condition1/ 
Clinical 
status2,3
Total % (n) 
n=268
With Polypharmacy % (n) 
n=229
P VALUE Without Polypharmacy % (n) 
n=39
P VALUE
Before After Before After Before After
Arterial Hypertension (n=79)
Positive 51.9 (40) 90.0 (54) 50.8 (31) 88.0 (44) 0.0003 56.2 (9) 100.0 (10) 0.0455
Negative 48.1 (37) 10.0 (6) 49.1 (30) 12.0 (6) 43.8 (7) -
Diabetes mellitus 2 (n=59)
Positive 34.0 (18) 72.3 (34) 38.6 (17) 74.4 (29) 0.0013 11.1 (1) 62.5 (5) 0.0833
Negative 66.0 (35) 27.7 (13) 61.4 (27) 25.6 (10) 88.2 (8) 47.5 (3)
Dyslipidemia (n=52) 
Positive 45.9 (17) 90.3 (28) 51.5 (17) 92.9 (26) 0.0114 - 66.7 (2) 0.0833
Negative 54.1 (20) 9.7 (3) 48.5 (16) 7.1 (2) 100.0 (4) 33.3 (1)
Anxiety (n=25) 
Positive 85.0 (17) 87.5 (14) 85.0 (17) 87.5 (14) - - - -
Negative 15.0 (3) 12.5 (2) 15.0 (3) 12.5 (2) - -
Depression (n=13) 
Positive 75.0 (9) 70.0 (7) 75.0 (9) 70.0 (7) 0.5637 - - -
Negative 25.0 (3) 30.0 (3) 25.0 (3) 30.0 (3) - -
Osteoporosis (n=13) 
Positive 100.0 (4) 100.0 (5) 100.0 (3) 100.0 (4) - 100.0 (1) 100.0 (1) -
Negative - - - - - -
Pain (n=9) 
Positive 60.0 (3) 80.0 (4) 60.0 (3) 80.0 (4) - - - -
Negative 40.0 (2) 20.0 (1) 40.0 (2) 20.0 (1) - -
Hypothyroidism (n=7) 
Positive 80.0 (4) 100.0 (3) 80.0 (4) 100.0 (3) - - - -
Negative 20.0 (1) - 20.0 (1) - - -
Dyspepsia (n=6) 
Positive 20.0 (1) 60.0 (3) 20.0 (1) 60.0 (3) - - - -
Negative 80.0 (4) 40.0 (2) 80.0 (4) 40.0 (2) - -
Epilepsy (n=5) 
Positive 100.0 (3) 100.0 (4) 100.0 (3) 100.0 (4) - - - -
Negative - - - - - -
Total
1 Number of patients with medical conditions stratified by clinical status and polypharmacy (in the column). 2 The classifications of clinical status 
named controlled (first appointment) or resolved, stable, improvement and partial improvement (last appointment) were aggregated as POSITIVE, 
and the classifications not controlled (first appointment) or no improvement, worsening, therapeutic failure and death (last appointment) were 
aggregated as NEGATIVE. 3 There are patients whose therapeutic goal records, or clinical status, in the first and last MTM visit were not described.
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parameters used to assess the effectiveness of treatment 
were the absence of pain, fractures and an increase in 
functional capacity. One limitation of the study was that 
bone densitometry was not performed at the beginning 
or at the end of the service. However, patients receiving 
MTM did not have access to this examination, and the 
goal of this study was to evaluate the impact of MTM 
services in real life. This limitation is conservative for the 
purposes of the study, since it points to an underestimate 
of the effectiveness of MTM services.
Adverse drug reactions were the most prevalent 
DRP in the present study. The patient’s attitudes toward 
medications, which reflect a personal evaluation of 
the drug as good or bad and harmful or beneficial, are 
thought to influence behaviour and adherence (Lyra 
Júnior et al., 2007; Mardby, Akerlind, Jorgensen, 2007; 
Phatak, Thomas, 2006; Osterberg, Blaschke, 2005; WHO, 
2003; Ajzen, 2001; Petty, Wegener, Fabrigar, 1997). A 
study by Correr et al. (2007) found that the safety of the 
treatment was the most significant risk factor for DRPs. 
TABLE II - Most used medications by patients referred to medication therapy management services, stratified by polypharmacy
Medication Total %
1 (n) 
n=402
With Polypharmacy %2 (n) 
n=344
Without Polypharmacy %2 (n) 
n=58
Simvastatin 12.7 (51) 86.3 (44) 13.7 (7)
Metformin 11.9 (48) 79.2 (38) 20.8 (10)
Hydrochlorothiazide 11.4 (46) 73.9 (34) 26.1 (12)
Captopril 10.0 (40) 80.0 (32) 20.0 (8)
AAS 8.0 (32) 87.5 (28) 12.5 (4)
Insulin NPH 7.0 (28) 96.4 (27) 3.6 (1)
Losartan 8.0 (27) 88.9 (24) 11.1 (3)
Glyburide 6.5 (26) 73.1 (19) 26.9 (7)
Nifedipine extended-release 5.0 (21) 85.7 (18) 14.3 (3)
Furosemide 4.2 (17) 100.0 (17) -
Propranolol 3.7 (15) 93.3 (14) 6.7 (1)
Omeprazole 3.7 (15) 86.7 (13) 13.3 (2)
Clonidine 3.0 (12) 100.0 (12) -
Alendronate Sodium 3.0 (12) 100.0 (12) -
Spironolactone 3.0 (12) 100.0 (12) -
1Calculated estimates considering the column totals. 2Calculated estimates considering the row totals in order to compare “with” 
and “without” polypharmacy.
TABLE III – Profile of DRPs stratified by polypharmacy
Pharmaceutical needs1 Types of DRP Total % (n) n=316
With Polypharmacy 
% (n) 
n=280
Without Polypharmacy 
% (n) 
n=36
Indication Unnecessary medication 15.5 (49) 91.8 (45) 8.2 (4)
Need for additional 
medication
5.1 (16) 81.3 (13) 18.7 (3)
Effectiveness Medicine ineffective 5.1 (16) 87.5 (14) 12.5 (2)
Low Dose 18.0 (57) 86.0 (49) 14.0 (8)
Safety Adverse reaction 31.0 (98) 89.9 (88) 10.1 (10)
High Dose 12.0 (38) 97.4 (37) 2.6 (1)
Adherence Non-adherence 13.3 (42) 81.0 (34) 19.0 (8) 
1Pharmacotherapies
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Adverse drug reactions can be associated with negative 
clinical outcomes in patients with chronic diseases, so 
interventions to solve this problem are very important 
(Gastelurrutia et al., 2011). A high occurrence of adverse 
drug reactions can lead to higher rates of treatment 
interruption (Vasconcelos et al., 2005; Firmo, Lima-Costa, 
Uchôa, 2004). Other authors pointed out the relationship 
between polypharmacy, adverse drug reactions and non-
adherence (Secoli, 2010; Rocha et al., 2008; Rozenfeld, 
2003).
Changes or recommendations for a change of a 
patient’s medication were the most common intervention 
to resolve the DRPs of adverse drug reactions. For 
instance, many patients were on captopril (n=40) and had 
presented with a dry cough. Also, a significant number of 
patients were using clonidine (n=12) – mainly men, who 
complained about adverse reactions such as dry mouth, 
bradycardia and impotence, and abandoned the treatment 
due to these effects. Clonidine is mentioned in the Beers 
criteria as a drug that has a high risk of adverse effects, 
including those that affect the central nervous system, 
orthostatic hypotension and bradycardia. It is interesting 
to note that the mean age of our patients was 63 years, 
which is considered elderly in Brazil, and clonidine should 
not be routinely used for the treatment of hypertension in 
this population (Gastelurrutia et al., 2011). Therefore, the 
pharmacist recommended that the physician change the 
antihypertensive drug to a safer medication. 
It was found that many diabetic patients were using 
non-selective beta blockers such as propranolol (n=10), 
which is contraindicated in these patients because of the 
difficulty in identifying symptoms of, and recovering 
from, hypoglycemia (Dipiro et al., 2011). In this case, 
a change to a selective beta blocker such as atenolol 
was recommended. Also, in some cases, a switch from 
metformin 850 mg once daily to metformin 500 mg slow 
release twice daily was suggested, depending on the 
occurrence of gastrointestinal intolerance (Dipiro et al., 
2011; Young et al., 2005). 
The DRP of low dose was also common, with 
the most frequent cause being an interaction between 
captopril and food. This result is in agreement with other 
studies, which also found that a low dose was the most 
prevalent DRP in clinical pharmacy services (Correr 
et al., 2007; Strand et al., 2004). The collaboration 
between pharmacists and physicians was essential 
in resolving and/or preventing DRPs in this study. 
The physicians were receptive to MTM pharmacists’ 
interventions. Collaborative working relationships were 
developed over time as MTM pharmacists started taking 
more responsibility for patient care and demonstrated 
competency.
The significant clinical impact of pharmaceutical 
care-based MTM, as shown by the improvement in the 
clinical status of the most prevalent health conditions from 
the first to the last MTM visit, should be highlighted. As 
previously underscored (Strand et al., 2004; Ramalho de 
Oliveira, Brummel, Miller, 2010), these positive results 
can be partly explained by the inclusion of a professional, 
an MTM pharmacist, whose main responsibility is to 
TABLE IV - Interventions carried out during delivery of medication therapy management services and therapeutic goals achieved
Intervention performed
Total 
% (n) 
n=307
Therapeutic goal  
achieved % (n) 
n=202
Therapeutic goal not achieved 
% (n) 
n=40
Change medicine 22.1 (68) 84.2 (48) 15.8 (9)
Interrupt pharmacotherapy 16.3 (50) 75.0 (27) 25.0 (9)
Patient instructions * 16.0 (49) 79.4 (27) 20.6 (7)
Change dose 11.1 (34) 75.0 (18) 25.0 (6)
Remove barriers to treatment 
adherence
9.8 (30) 96.2 (26) 3.7 (1)
Start monitoring of adverse 
reaction
8.1 (25) 76.0 (19) 24.0 (6)
Start laboratory monitoring 6.8 (21) 94.1 (16) 5.9 (1)
Start new pharmacotherapy 4.9 (15) 90.9 (10) 9.1 (1)
Provide reminders with 
timetables for medicines
4.9 (15) 100.0 (11) 0.0 (0)
* Appropriate medication use, nutrition education and information about physical activity.
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improve drug therapy outcomes through collaboration 
with the patient and the health-care team. Moreover, this 
professional follows a standardized practice and a logical 
decision-making process that is based on science and 
reproducible in the real world. 
 The use of patient records as a source of 
information is another limitation of this study, as reported 
by other authors (Kahn, Ranade, 2010). This emphasizes 
the need for an improvement in the documentation 
process, as demonstrated by other authors (Sousa et al., 
2012; Kahn, Ranade, 2010; Becker, Bjornson, Kuhle, 
2004).
CONCLUSIONS
The study showed that a large proportion of patients 
using medications in the primary care setting were 
not reaching their therapy goals when cared for by the 
traditional health-care team. The management of patients’ 
drug therapy by MTM pharmacists improves the control of 
medical conditions, particularly chronic conditions. There 
was a positive association between polypharmacy and 
occurrence of DRPs, demonstrating that polypharmacy 
should be a criterion for the referral of patients to MTM 
services. Considering that in this study most drugs were 
used to treat chronic conditions such as hypertension, 
diabetes and hyperlipidemia, the effective training of 
pharmacists in these conditions and their treatments might 
positively affect the health outcomes in primary care. The 
Brazilian public health system needs to adopt measures to 
improve control and prevent aggravation of chronic health 
conditions, and the provision of MTM services might be 
one of these measures. 
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